How to cite item

Second-line treatment in EGFR-unselected patients: is it time to close one arm of this river’s DELTA?

   
@article{JTD4096,
	author = {Daniela Morales-Espinosa and Rafael Rosell},
	title = {Second-line treatment in EGFR-unselected patients: is it time to close one arm of this river’s DELTA?},
	journal = {Journal of Thoracic Disease},
	volume = {7},
	number = {3},
	year = {2015},
	keywords = {},
	abstract = {Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death worldwide. Despite advances in treatment, most patients will eventually relapse. Nowadays, there are four monotherapy options available for second-line standard treatment for patients with stage IV NSCLC: pemetrexed (for non-squamous NSCLC), docetaxel, erlotinib or gefitinib (1,2). Current practice guidelines do not require epidermal growth factor receptor (EGFR) mutation status testing before initiating a second-line therapy with an EGFR tyrosine kinase inhibitor (TKI).},
	issn = {2077-6624},	url = {https://jtd.amegroups.org/article/view/4096}
}